D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Read the full article here

Related Articles